Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience

BACKGROUND: Vancomycin treatment of complicated Gram-positive infections is associated with laboratory monitoring, nephrotoxicity, and multiple daily dosing. Oritavancin, a lipoglycopeptide antibiotic with a once-weekly dosing strategy and similar but slightly broader spectrum of activity, presents...

Descripción completa

Detalles Bibliográficos
Autores principales: Brownell, Lauren E., Adamsick, Meagan L., McCreary, Erin K., Vanderloo, Joshua P., Ernst, Erika J., Jackson, Emily R., Schulz, Lucas T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334320/
https://www.ncbi.nlm.nih.gov/pubmed/32592120
http://dx.doi.org/10.1007/s40801-020-00192-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334320/
https://www.ncbi.nlm.nih.gov/pubmed/32592120
http://dx.doi.org/10.1007/s40801-020-00192-w

Ejemplares similares